England's National Health Services plans to offer Eli Lilly's weight-loss drugs to nearly a quarter million people as part of a three-year plan, UK's drugs cost regulator said on Thursday.

While Mounjaro was cleared for use in England last year, Lilly put its launch on hold until its pre-filled injection device, Kwikpen, was endorsed in January by the Medicines & Healthcare products Regulatory Agency (MHRA). The product was cleared for both type 2 diabetes and obesity patients.

The announcement is a blow to the compounding pharmacies that have made cheaper, off-brand versions of the medication The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over,

The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making custom-made versions.

Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the U.S., threatening to upend the many knockoffs that became popular when patients couldn’t find the brand-name medicines.

Nearly 250,000 people in England could be taking Eli Lilly & Co.’s blockbuster weight-loss drug Mounjaro within three years as part of a phased rollout of the popular drug.

The U.S. Food and Drug Administration removed Eli Lilly's blockbuster weight-loss and diabetes drugs from its shortage list late on Wednesday, likely piling pressure on firms selling cheaper versions known as compounded drugs.